Coya Therapeutics (COYA) announced the FDA has granted Fast Track Designation for COYA 302, an investigational biologic combination therapy with a dual mechanism of action, for the treatment of amyotrophic lateral sclerosis. Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS.
Arun Swaminathan, CEO of Coya, said: "At Coya, we remain fully committed to advancing our lead biologic candidate, COYA 302, through the regulatory process with the ultimate goal of delivering-pending FDA approval-a safe and effective treatment for patients living with ALS and their families."
In pre-market trading on NasdaqCM, Coya shares are up 3.83 percent to $4.34.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.